Engineered immune cells take aim at stubborn leukemia
Disease control
Terminated
This early-stage trial tested a new therapy for patients with acute myeloid leukemia (AML) that had returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack cancer cells carrying a specific marker (CD123).…
Phase: PHASE1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC